Stock GNPX GENPREX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Genprex, Inc.

Equities

GNPX

US3724462037

Delayed Nasdaq
Other stock markets
 03:28:40 2024-04-16 pm EDT 		5-day change 1st Jan Change
2.28 USD -2.98% Intraday chart for Genprex, Inc. -25.73% -75.22%
Apr. 03 Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer CI
Apr. 02 Genprex, Inc. Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System CI

Evolution of the average Target Price on Genprex, Inc.

Price target over the last 5 years

History of analyst recommendation changes

b88add81b0ba6fcd6b5362.NR7Fh0-ExF-w7dg6SQZ-xKq8YJb-9PVQ-kTeW3MLq-k.TWSm4SXAohbk2OBoeEg9tMjKFcS9hc0XkgasKjBkkt9Wd_fLPciBaYesqw~064c96228d78178fe6a9351f034a504d

Analyst Recommendations on Genprex, Inc.

HC Wainwright Initiates Genprex With Buy Rating, $10 Price Target MT
Dawson James Initiates Genprex at Buy Rating With $3 Price Target MT
GENPREX : National Securities Starts Genprex at Buy With $7 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.35 USD
Average target price
165 USD
Spread / Average Target
+6,921.28%
High Price Target
320 USD
Spread / Highest target
+13,517.02%
Low Price Target
10 USD
Spread / Lowest Target
+325.53%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Genprex, Inc.

HC Wainwright
Dawson James
National Securities

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. GNPX Stock
  4. Consensus Genprex, Inc.